Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial

IMPORTANCE: Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention. OBJECTIVE: To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine prevention. DESIGN,...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Neurol
Главные авторы: Skljarevski, Vladimir, Oakes, Tina M., Zhang, Qi, Ferguson, Margaret B., Martinez, James, Camporeale, Angelo, Johnson, Kirk W., Shan, Qiuling, Carter, Jeffrey, Schacht, Aaron, Goadsby, Peter J., Dodick, David W.
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2017
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838630/
https://ncbi.nlm.nih.gov/pubmed/29255900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.3859
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы